BioXcel Therapeutics, Inc

(NASDAQ:BTAI)

Latest On BioXcel Therapeutics, Inc (BTAI):

Date/Time Type Description Signal Details
2023-05-29 08:05 ESTNewsBioXcel Therapeutics: Serenity III Part 1 Didn't Meet Primary Endpoints, Part 2 WillN/A
2023-05-25 18:49 ESTNewsBioXcel trades lower after mixed results for lower dose Igalmi for bipolar agitationN/A
2023-05-22 05:35 ESTNewsBioXcel Therapeutics: Clinical Trial Milestones Drive Stock But Slow Market Adoption PersistsN/A
2023-05-11 17:36 ESTNewsBioXcel Therapeutics: It Is All About Key Upcoming Clinical Data ReadoutsN/A
2023-05-08 21:53 ESTNewsBioXcel Therapeutics, Inc. (BTAI) Q1 2023 Earnings Call TranscriptN/A
2023-05-08 21:53 ESTNewsBioXcel closes up 14% despite lackluster quarterly reportN/A
2023-05-08 08:36 ESTNewsBioXcel Therapeutics GAAP EPS of -$1.84 misses by $0.18, revenue of $0.21M misses by $0.11MN/A
2023-05-06 00:52 ESTNewsBioXcel Therapeutics Q1 2023 Earnings PreviewN/A
2023-04-27 03:44 ESTNewsBioXcel Therapeutics: All Eyes On Igalmi's Ramp, Reiterating Hold RatingN/A
2023-04-05 20:01 ESTNewsSlow Adoption: BioXcel's Igalmi Struggles To Gain TractionN/A
2023-03-17 06:34 ESTNewsBioXcel Therapeutics' Igalmi Commercial Launch: Not As Bad As Some May ThinkN/A
2023-03-10 21:07 ESTNewsBioXcel cut to Hold at Jefferies on uncertain commercial opportunityN/A
2023-03-09 14:10 ESTNewsBioXcel Therapeutics GAAP EPS of -$1.95 misses by $0.51, revenue of $0.24M misses by $0.84MN/A
2023-03-09 14:10 ESTNewsBioXcel Therapeutics, Inc. (BTAI) Q4 2022 Earnings Call TranscriptN/A
2023-02-17 14:22 ESTNewsBioXcel BXCL701: Another Step Forward In The Race For An mCRPC TreatmentN/A
2023-01-31 13:28 ESTNewsKaruna appoints former BioXcel exec as chief commercial officerN/A
2023-01-31 13:28 ESTNewsBioXcel Therapeutics: IGALMI Is Likely A Dud In The Real-WorldN/A
2023-01-30 12:10 ESTNewsBioXcel Therapeutics: Boldly Entering The Danger Zone With Launch Of IGALMIN/A
2023-01-11 08:28 ESTNewsBioXcel's BXCL701, Keytruda combo shows promise in mid-stage trial for prostate cancerN/A
2022-12-02 02:43 ESTNewsBioXcel upgraded at Goldman Sachs on recent underperformanceN/A
2022-11-30 14:45 ESTNewsBioXcel starts dosing in trial of BXCL501 to treat agitation in bipolar, schizophreniaN/A
2022-11-14 23:39 ESTNewsSeeking Treatment For Agitation In Alzheimer's Patients: A Race For A Multi-Billion Opportunity, And BioXcel's BXCL501 Has The EdgeN/A
2022-11-11 07:18 ESTNewsBioXcel Therapeutics, Inc. (BTAI) Q3 2022 Earnings Call TranscriptN/A
2022-11-10 14:14 ESTNewsBioXcel Therapeutics GAAP EPS of -$1.49 misses by $0.15, revenue of $0.14MN/A
2022-11-10 14:14 ESTNewsBioXcel stock soars 17% as lead drug Igalmi starts to bring in revenueN/A
2022-11-09 21:36 ESTNewsBioXcel Therapeutics Q3 2022 Earnings PreviewN/A
2022-08-28 18:48 ESTNewsBioXcel Therapeutics: Igalmi's Commercial Uncertainty Remains, Downgrading To A HoldN/A
2022-08-09 20:06 ESTNewsBioXcel Therapeutics GAAP EPS of -$1.35 misses by $0.12N/A
2022-08-09 20:06 ESTNewsBioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-09 20:06 ESTNewsBioXcel stock falls ~9% as Q2 net loss widensN/A
2022-08-08 23:15 ESTNewsBioXcel Therapeutics Q2 2022 Earnings PreviewN/A
2022-07-19 14:26 ESTNewsBioXcel Therapeutics: BXCL501 For Acute Agitation In Patients With Dementia And Alzheimer's - A Great AssetN/A
2022-05-18 23:53 ESTNewsBioXcel's Igalmi: Potential Market For Acute Agitation In Esquizofrenia And Bipolar PatientsN/A
2022-05-10 03:12 ESTNewsBioXcel stock falls as Q1 net loss widens Y/Y but Igalmi approval positions to "realize" FY22 goalsN/A
2022-05-10 03:12 ESTNewsBioXcel Therapeutics (BTAI) CEO, Vimal Mehta on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-09 07:21 ESTNewsBioXcel Therapeutics GAAP EPS of -$1.12 beats by $0.01N/A
2022-04-19 20:02 ESTNewsBioXcel Therapeutics rises after announcing $260M strategic financing, formation of new unitN/A
2022-04-09 04:56 ESTNewsBioXcel Therapeutics: At A Turning Point After The Approval Of BXCL501N/A
2022-04-06 13:08 ESTNewsBioXcel soars on FDA approval for psychiatric therapyN/A
2022-04-06 13:08 ESTNewsBioXcel price target raised at BofA after FDA approval for IgalmiN/A
2022-03-25 16:20 ESTNewsBioXcel rises 15% ahead of early April FDA decision on agitation drug BXCL501N/A
2022-03-22 19:29 ESTNewsBioXcel Therapeutics Inc.: Speculative Buy To Play The PDUFA For BXCL501 In AprilN/A
2022-03-11 08:26 ESTNewsBioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-10 13:20 ESTNewsBioXcel Therapeutics GAAP EPS of -$0.93 beats by $0.21N/A
2022-03-10 13:20 ESTNewsBioXcel Therapeutics down 6% even with bottom line beatN/A
2022-03-05 13:07 ESTNewsBioxcel Therapeutics: What To Expect From The Upcoming PDFAN/A
2022-02-26 00:37 ESTNewsBioXcel Therapeutics (BTAI) Presents At Global Healthcare Virtual Conference - SlideshowN/A
2022-02-22 19:58 ESTNewsBioXCel agitation with bipolar drug meets primary and secondary endpoints in phase 3N/A
2022-01-26 18:55 ESTNewsBioXcel Therapeutics: Facing An Important PDUFA Date In A Few WeeksN/A
2021-12-08 03:29 ESTNewsBioXcel: Slump After PDUFA Extension Presents Buying OpportunityN/A

About BioXcel Therapeutics, Inc (BTAI):

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

BTAI Quotes by TradingView

See Advanced Chart

General

  • Name BioXcel Therapeutics, Inc
  • Symbol BTAI
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 50
  • Fiscal Year EndDecember
  • IPO Date2018-03-08
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.bioxceltherapeutics.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 5.57
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$4.41
  • Next Year EPS Estimate -$3.44
  • Next Quarter EPS Estimate -$0.98
  • Return on Assets -40%
  • Return on Equity -70%
  • Earnings Per Share -$1.77
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 1.08 billion
  • EBITDA -28411000
  • PE Ratio -0.23
  • Analyst Target Price $113.36
  • Book Value Per Share $8.47
View More

Share Statistics

  • Shares Outstanding 24.57 million
  • Shares Float 15.26 million
  • % Held by Insiders 3980%
  • % Held by Institutions 53.92%
  • Shares Short 3.61 million
  • Shares Short Prior Month 3.57 million
  • Short Ratio 6.51
  • Short % of Float 25%
  • Short % of Shares Outstanding 15%
View More

Technicals

  • Beta 1.31
  • 52 Week High $67.74
  • 52 Week Low $14.27
  • 50 Day Moving Average 52.38
  • 200 Day Moving Average 49.13
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

BioXcel Therapeutics, Inc (BTAI) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

BioXcel Therapeutics, Inc (BTAI) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-11$N/A-$0.87-$0.914.78%
2020-09-302020-11-12$N/A-$1.07-$0.79-35.44%
2020-06-302020-08-14$N/A-$1.06-$0.78-35.32%
2020-03-312020-05-12$N/A-$0.79-$0.61-29.93%
2019-12-312020-03-09$N/A-$0.45-$0.6934.55%
2019-09-302019-11-14$N/A-$0.57-$0.605%
2019-06-302019-08-06$N/A-$0.54-$0.6010.54%
2019-03-312019-05-07$N/A-$0.46-$0.5313.37%
2018-12-312019-03-07$N/A-$0.46-$0.37-23.03%
2018-09-302018-11-09$N/A-$0.31-$0.29-7.53%
2018-06-302018-08-08$N/A-$0.19-$0.3137.91%
2018-03-312018-05-14$N/A-$0.37-$0.27-38.99%

BioXcel Therapeutics, Inc (BTAI) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

BioXcel Therapeutics, Inc (BTAI) Chart:

BioXcel Therapeutics, Inc (BTAI) News:

Below you will find a list of latest news for BioXcel Therapeutics, Inc (BTAI) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

BioXcel Therapeutics, Inc (BTAI) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-01-170.50.2CALL0 560TRUE00
2025-01-1710.06CALL70 190128.78FALSE-0.04-0.4
2025-01-171.50.1CALL0 2090FALSE00
2025-01-1720.2CALL0 5510FALSE00
2025-01-172.50.05CALL0 530FALSE00
2025-01-1730.15CALL0 800FALSE00
2025-01-173.50.05CALL0 6060FALSE00
2025-01-1740.25CALL0 1740FALSE00
2025-01-174.50.1CALL0 2670FALSE00
2025-01-1750.15CALL0 5440FALSE00
2025-01-175.50.33CALL0 300FALSE00
2025-01-177.50.05CALL0 1520FALSE00
2025-01-170.50PUT0 00FALSE00
2025-01-1710.4PUT0 00TRUE00
2025-01-171.50.5PUT0 380TRUE00
2025-01-1721.05PUT0 1110TRUE00
2025-01-172.51.04PUT0 53302.56TRUE00
2025-01-1732.5PUT0 28192.81TRUE00
2025-01-173.50PUT0 0242.48TRUE00
2025-01-1742.15PUT0 0219.64TRUE00
2025-01-174.50PUT0 0339.25TRUE00
2025-01-1753.91PUT0 220TRUE00
2025-01-175.53.6PUT0 0358.87TRUE00
2025-01-177.56.4PUT0 15625.15TRUE00
2025-02-2110.6CALL0 10FALSE00
2025-02-2120.05CALL0 70FALSE00
2025-02-212.50.4CALL0 650FALSE00
2025-02-2140CALL0 00FALSE00
2025-02-2150.2CALL0 3500FALSE00
2025-02-217.50CALL0 00FALSE00
2025-02-2110PUT0 110TRUE00
2025-02-2120PUT0 00TRUE00
2025-02-212.50PUT0 00TRUE00
2025-02-2140PUT0 00TRUE00
2025-02-2150PUT0 0216.86TRUE00
2025-02-217.50PUT0 0252.72TRUE00
2025-05-1610.15CALL0 130FALSE00
2025-05-1620CALL0 00FALSE00
2025-05-1630CALL0 00FALSE00
2025-05-1640CALL0 00FALSE00
2025-05-1610PUT0 00TRUE00
2025-05-1620PUT0 00TRUE00
2025-05-1630PUT0 0839.81TRUE00
2025-05-1640PUT0 0166.08TRUE00
2026-01-160.50.35CALL0 1830TRUE00
2026-01-1610.25CALL0 54159.19FALSE00
2026-01-161.51CALL0 60FALSE00
2026-01-1620.67CALL0 80FALSE00
2026-01-162.50.45CALL0 2130FALSE00
2026-01-1630.2CALL0 359176.75FALSE00
2026-01-163.52.05CALL0 10FALSE00
2026-01-1641.2CALL0 110FALSE00
2026-01-164.51.75CALL0 60FALSE00
2026-01-1650.1CALL0 510FALSE00
2026-01-165.50CALL0 00FALSE00
2026-01-167.50.73CALL0 250FALSE00
2026-01-160.50PUT0 00FALSE00
2026-01-1610.45PUT0 40TRUE00
2026-01-161.50.75PUT0 20TRUE00
2026-01-1621PUT0 10TRUE00
2026-01-162.52PUT0 740TRUE00
2026-01-1631.61PUT0 10TRUE00
2026-01-163.50PUT0 00TRUE00
2026-01-1642.6PUT0 2180.31TRUE00
2026-01-164.50PUT0 00TRUE00
2026-01-1654.23PUT0 20171.78TRUE00
2026-01-165.52.6PUT0 20TRUE00
2026-01-167.55.31PUT0 00TRUE00

Latest BTAI Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST100$9.23
Jun 13, 2022 7:59 PM EST9$9.235
Jun 13, 2022 7:59 PM EST19$9.24
Jun 13, 2022 7:59 PM EST41$9.25
Jun 13, 2022 7:59 PM EST100$9.24

BioXcel Therapeutics, Inc (BTAI) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465920076490/0001104659-20-076490-index.htm
2019-04-04UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1720893/000000000019006497/0000000000-19-006497-index.htm
2019-01-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1720893/000031506619000020/0000315066-19-000020-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1720893/000031506620000854/0000315066-20-000854-index.htm
2019-04-01DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1720893/000104746919001846/0001047469-19-001846-index.htm
2019-05-20424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1720893/000104746919003199/0001047469-19-003199-index.htm
2019-09-25424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1720893/000104746919005447/0001047469-19-005447-index.htm
2019-09-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1720893/000104746919005498/0001047469-19-005498-index.htm
2020-02-19424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1720893/000104746920000943/0001047469-20-000943-index.htm
2020-02-21424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1720893/000104746920000974/0001047469-20-000974-index.htm
2020-07-27S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuershttps://www.sec.gov/Archives/edgar/data/1720893/000104746920004257/0001047469-20-004257-index.htm
2020-07-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1720893/000104746920004260/0001047469-20-004260-index.htm
2020-07-31424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1720893/000104746920004337/0001047469-20-004337-index.htm
2018-09-14SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1720893/000106299318003740/0001062993-18-003740-index.htm
2020-02-18SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1720893/000106299320001040/0001062993-20-001040-index.htm
2020-02-24SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1720893/000106299320001128/0001062993-20-001128-index.htm
2020-03-06SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1720893/000106299320001271/0001062993-20-001271-index.htm
2018-05-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465918034817/0001104659-18-034817-index.htm
2018-06-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465918038026/0001104659-18-038026-index.htm
2018-06-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465918038902/0001104659-18-038902-index.htm
2018-06-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465918038943/0001104659-18-038943-index.htm
2018-06-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465918042589/0001104659-18-042589-index.htm
2018-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465918046760/0001104659-18-046760-index.htm
2018-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465918050492/0001104659-18-050492-index.htm
2018-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1720893/000110465918050505/0001104659-18-050505-index.htm
2018-08-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465918053383/0001104659-18-053383-index.htm
2018-09-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465918058750/0001104659-18-058750-index.htm
2018-10-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465918064487/0001104659-18-064487-index.htm
2018-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465918065994/0001104659-18-065994-index.htm
2018-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465918068277/0001104659-18-068277-index.htm
2018-11-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465918070793/0001104659-18-070793-index.htm
2018-11-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465918070795/0001104659-18-070795-index.htm
2018-11-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465918070826/0001104659-18-070826-index.htm
2018-11-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465918070832/0001104659-18-070832-index.htm
2018-11-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465918070875/0001104659-18-070875-index.htm
2018-11-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465918070876/0001104659-18-070876-index.htm
2018-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465918071215/0001104659-18-071215-index.htm
2018-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465918071220/0001104659-18-071220-index.htm
2018-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465918071405/0001104659-18-071405-index.htm
2018-12-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465918071465/0001104659-18-071465-index.htm
2018-12-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465918071741/0001104659-18-071741-index.htm
2018-12-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465918071881/0001104659-18-071881-index.htm
2018-12-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465918072470/0001104659-18-072470-index.htm
2018-12-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465918072547/0001104659-18-072547-index.htm
2018-12-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465918073106/0001104659-18-073106-index.htm
2018-12-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465918074140/0001104659-18-074140-index.htm
2018-12-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465918074908/0001104659-18-074908-index.htm
2019-01-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465919000498/0001104659-19-000498-index.htm
2019-02-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465919005571/0001104659-19-005571-index.htm
2019-02-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465919007130/0001104659-19-007130-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1720893/000110465919008368/0001104659-19-008368-index.htm
2019-03-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465919012477/0001104659-19-012477-index.htm
2019-03-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465919013402/0001104659-19-013402-index.htm
2019-03-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465919013865/0001104659-19-013865-index.htm
2019-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465919014314/0001104659-19-014314-index.htm
2019-03-14S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1720893/000110465919014871/0001104659-19-014871-index.htm
2019-03-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465919015667/0001104659-19-015667-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465919015669/0001104659-19-015669-index.htm
2019-03-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465919017151/0001104659-19-017151-index.htm
2019-04-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465919018965/0001104659-19-018965-index.htm
2019-04-01RWRegistration Withdrawal Requesthttps://www.sec.gov/Archives/edgar/data/1720893/000110465919019011/0001104659-19-019011-index.htm
2019-04-01S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1720893/000110465919019020/0001104659-19-019020-index.htm
2019-04-02DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1720893/000110465919019027/0001104659-19-019027-index.htm
2019-04-02CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1720893/000110465919019429/0001104659-19-019429-index.htm
2019-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465919027345/0001104659-19-027345-index.htm
2019-05-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465919030423/0001104659-19-030423-index.htm
2019-05-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465919030429/0001104659-19-030429-index.htm
2019-05-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465919030930/0001104659-19-030930-index.htm
2019-05-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465919032141/0001104659-19-032141-index.htm
2019-05-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465919032142/0001104659-19-032142-index.htm
2019-05-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465919032143/0001104659-19-032143-index.htm
2019-05-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465919032453/0001104659-19-032453-index.htm
2019-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465919036496/0001104659-19-036496-index.htm
2019-07-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465919041197/0001104659-19-041197-index.htm
2019-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465919044148/0001104659-19-044148-index.htm
2019-08-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465919045930/0001104659-19-045930-index.htm
2019-08-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465919045931/0001104659-19-045931-index.htm
2019-08-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465919046363/0001104659-19-046363-index.htm
2019-08-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465919046520/0001104659-19-046520-index.htm
2019-08-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465919047150/0001104659-19-047150-index.htm
2019-08-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465919047308/0001104659-19-047308-index.htm
2019-09-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465919051349/0001104659-19-051349-index.htm
2019-09-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465919051834/0001104659-19-051834-index.htm
2019-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465919063711/0001104659-19-063711-index.htm
2019-11-26S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1720893/000110465919067684/0001104659-19-067684-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465920003268/0001104659-20-003268-index.htm
2020-02-143/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465920021799/0001104659-20-021799-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465920021807/0001104659-20-021807-index.htm
2020-02-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465920022880/0001104659-20-022880-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465920022899/0001104659-20-022899-index.htm
2020-02-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465920023567/0001104659-20-023567-index.htm
2020-03-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465920030473/0001104659-20-030473-index.htm
2020-04-06DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1720893/000110465920043400/0001104659-20-043400-index.htm
2020-04-06DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1720893/000110465920043401/0001104659-20-043401-index.htm
2020-04-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465920046505/0001104659-20-046505-index.htm
2020-04-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465920052445/0001104659-20-052445-index.htm
2020-05-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465920059966/0001104659-20-059966-index.htm
2020-05-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1720893/000110465920061005/0001104659-20-061005-index.htm
2020-05-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465920061009/0001104659-20-061009-index.htm
2020-05-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465920061013/0001104659-20-061013-index.htm
2020-05-133/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465920061016/0001104659-20-061016-index.htm
2020-05-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465920064759/0001104659-20-064759-index.htm
2020-05-21S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1720893/000110465920064878/0001104659-20-064878-index.htm
2020-05-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465920065871/0001104659-20-065871-index.htm
2020-05-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465920065873/0001104659-20-065873-index.htm
2020-05-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465920065876/0001104659-20-065876-index.htm
2020-05-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465920067050/0001104659-20-067050-index.htm
2020-05-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465920067052/0001104659-20-067052-index.htm
2020-05-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465920067056/0001104659-20-067056-index.htm
2020-05-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465920067057/0001104659-20-067057-index.htm
2020-06-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465920074174/0001104659-20-074174-index.htm
2020-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465920074176/0001104659-20-074176-index.htm
2020-06-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465920076143/0001104659-20-076143-index.htm
2020-06-233Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000110465920076144/0001104659-20-076144-index.htm
2020-06-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465920076490/0001104659-20-076490-index.htm
2020-07-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465920086817/0001104659-20-086817-index.htm
2020-07-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465920089171/0001104659-20-089171-index.htm
2020-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000110465920095015/0001104659-20-095015-index.htm
2020-05-043Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1720893/000119248220000311/0001192482-20-000311-index.htm
2018-11-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1720893/000155837018009106/0001558370-18-009106-index.htm
2018-11-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1720893/000155837018009109/0001558370-18-009109-index.htm
2019-03-1210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1720893/000155837019001798/0001558370-19-001798-index.htm
2019-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1720893/000155837019004262/0001558370-19-004262-index.htm
2019-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1720893/000155837019007155/0001558370-19-007155-index.htm
2019-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1720893/000155837019010995/0001558370-19-010995-index.htm
2020-03-0910-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1720893/000155837020002196/0001558370-20-002196-index.htm
2020-05-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1720893/000155837020006435/0001558370-20-006435-index.htm
2020-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1720893/000155837020010611/0001558370-20-010611-index.htm
2019-04-04EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1720893/999999999519000611/9999999995-19-000611-index.htm
2018-12-20CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1720893/999999999718009626/9999999997-18-009626-index.htm

BioXcel Therapeutics, Inc (BTAI) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of BioXcel Therapeutics, Inc (BTAI). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 3980%
Institutional Ownership: 5392%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-11-29Krishnan NandabalanDirectorBuy1,000.004.924,915.001,000.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918070832/0001104659-18-070832-index.htm
2018-11-30Richard I SteinhartChief Financial OfficerBuy500.005.002,500.001,000.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918070876/0001104659-18-070876-index.htm
2018-11-30Vimal MehtaCEO, President, SecretaryBuy300.005.201,560.001,000.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918070826/0001104659-18-070826-index.htm
2018-12-03Vimal MehtaCEO, President, SecretaryBuy200.005.101,020.001,200.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918071220/0001104659-18-071220-index.htm
2018-12-03Vimal MehtaCEO, President, SecretaryBuy100.005.13513.001,300.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918071220/0001104659-18-071220-index.htm
2018-12-03Frank YoccaChief Scientific OfficerBuy450.005.232,353.461,400.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918071465/0001104659-18-071465-index.htm
2018-12-03Vimal MehtaCEO, President, SecretaryBuy100.005.14514.001,400.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918071220/0001104659-18-071220-index.htm
2018-12-04PETER MUELLERDirectorBuy1,076.005.095,476.84146,594.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918071741/0001104659-18-071741-index.htm
2018-12-04PETER MUELLERDirectorBuy325.005.111,660.75146,919.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918071741/0001104659-18-071741-index.htm
2018-12-04PETER MUELLERDirectorBuy344.005.121,761.28147,263.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918071741/0001104659-18-071741-index.htm
2018-12-04PETER MUELLERDirectorBuy200.005.131,026.00147,463.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918071741/0001104659-18-071741-index.htm
2018-12-04PETER MUELLERDirectorBuy2,062.005.1510,619.30149,525.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918071741/0001104659-18-071741-index.htm
2018-12-03Richard I SteinhartChief Financial OfficerBuy500.005.202,599.951,500.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918071215/0001104659-18-071215-index.htm
2018-12-03Vimal MehtaCEO, President, SecretaryBuy100.005.18518.001,500.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918071220/0001104659-18-071220-index.htm
2018-12-06PETER MUELLERDirectorBuy1,295.005.006,475.00150,820.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918071881/0001104659-18-071881-index.htm
2018-12-06PETER MUELLERDirectorBuy100.005.01501.00150,920.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918071881/0001104659-18-071881-index.htm
2018-12-07PETER MUELLERDirectorBuy495.005.002,475.00151,415.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918071881/0001104659-18-071881-index.htm
2018-12-07PETER MUELLERDirectorBuy6,905.005.0134,594.05158,320.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918071881/0001104659-18-071881-index.htm
2019-08-21PETER MUELLERDirectorBuy1,800.008.4215,156.00160,120.00https://www.sec.gov/Archives/edgar/data/1720893/000110465919047150/0001104659-19-047150-index.htm
2019-08-22PETER MUELLERDirectorBuy6,646.008.8358,684.18166,766.00https://www.sec.gov/Archives/edgar/data/1720893/000110465919047150/0001104659-19-047150-index.htm
2019-08-23PETER MUELLERDirectorBuy1,554.009.3414,514.36168,320.00https://www.sec.gov/Archives/edgar/data/1720893/000110465919047308/0001104659-19-047308-index.htm
2018-12-04Frank YoccaChief Scientific OfficerBuy450.005.202,338.791,850.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918071465/0001104659-18-071465-index.htm
2018-12-03Vimal MehtaCEO, President, SecretaryBuy500.005.202,600.002,000.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918071220/0001104659-18-071220-index.htm
2018-12-04Vimal MehtaCEO, President, SecretaryBuy500.005.092,545.002,500.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918071405/0001104659-18-071405-index.htm
2018-11-30Vimal MehtaCEO, President, SecretaryBuy300.005.041,512.00300.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918070826/0001104659-18-070826-index.htm
2018-12-04Vimal MehtaCEO, President, SecretaryBuy500.005.152,575.003,000.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918071405/0001104659-18-071405-index.htm
2018-12-14Vimal MehtaCEO, President, SecretaryBuy800.004.273,416.003,800.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918073106/0001104659-18-073106-index.htm
2018-12-14Vimal MehtaCEO, President, SecretaryBuy200.004.32864.004,000.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918073106/0001104659-18-073106-index.htm
2018-12-14Vimal MehtaCEO, President, SecretaryBuy500.004.482,240.004,500.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918073106/0001104659-18-073106-index.htm
2018-12-14Vimal MehtaCEO, President, SecretaryBuy400.004.491,796.004,900.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918073106/0001104659-18-073106-index.htm
2018-11-29Frank YoccaChief Scientific OfficerBuy500.005.022,511.15500.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918070795/0001104659-18-070795-index.htm
2018-11-29Richard I SteinhartChief Financial OfficerBuy500.005.002,500.00500.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918070793/0001104659-18-070793-index.htm
2018-12-14Vimal MehtaCEO, President, SecretaryBuy100.004.50450.005,000.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918073106/0001104659-18-073106-index.htm
2018-11-30Vimal MehtaCEO, President, SecretaryBuy300.005.051,515.00600.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918070826/0001104659-18-070826-index.htm
2019-08-13Vimal MehtaCEO, President & SecretaryBuy1,000.008.758,750.006,000.00https://www.sec.gov/Archives/edgar/data/1720893/000110465919045931/0001104659-19-045931-index.htm
2019-08-14Vimal MehtaCEO, President & SecretaryBuy358.008.443,021.526,358.00https://www.sec.gov/Archives/edgar/data/1720893/000110465919046363/0001104659-19-046363-index.htm
2018-11-30Vimal MehtaCEO, President, SecretaryBuy100.005.17517.00700.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918070826/0001104659-18-070826-index.htm
2019-08-13Frank YoccaChief Scientific OfficerBuy6,547.008.6756,762.498,397.00https://www.sec.gov/Archives/edgar/data/1720893/000110465919045930/0001104659-19-045930-index.htm
2020-02-14Frank YoccaChief Scientific OfficerBuy80,000.000.4132,800.0088,397.00https://www.sec.gov/Archives/edgar/data/1720893/000110465920022899/0001104659-20-022899-index.htm
2019-08-15Vimal MehtaCEO, President & SecretaryBuy2,625.008.6722,758.758,983.00https://www.sec.gov/Archives/edgar/data/1720893/000110465919046363/0001104659-19-046363-index.htm
2020-02-24Krishnan NandabalanDirectorSell300,000.0030.089,024,000.009,180,000.00https://www.sec.gov/Archives/edgar/data/1720893/000110465920061009/0001104659-20-061009-index.htm
2020-02-24Vimal MehtaCEO, President and SecretarySell300,000.0030.089,024,000.009,180,000.00https://www.sec.gov/Archives/edgar/data/1720893/000110465920061013/0001104659-20-061013-index.htm
2018-11-30Frank YoccaChief Scientific OfficerBuy450.005.202,339.55950.00https://www.sec.gov/Archives/edgar/data/1720893/000110465918070875/0001104659-18-070875-index.htm
2019-08-16Vimal MehtaCEO, President and SecretaryBuy974.008.898,658.869,957.00https://www.sec.gov/Archives/edgar/data/1720893/000110465919046520/0001104659-19-046520-index.htm